Acute Leukemia Perspective

 
 
  • Cancer Moonshot: We Have Liftoff Initial reaction to the Moonshot ranged from cynicism to guarded optimism, but no one denies that momentum is building for this national cancer initiative -- and Big Data are the rocket boosters.
  • What's Hot in Hematologic Malignancies   Dr Bruce Cheson gives a sneak preview of the presentations in hematologic malignancies at ASCO 2016, with a look at new agents, refined combinations, and strategies to reduce toxicities.
  • Takeaways From ASH 2015: CAR T cell Therapy for Myeloma   Dr Saad Usmani highlights the key takeaways on CAR T cell therapy for myeloma from the 57th American Society of Hematology Annual Meeting.
  • Takeaways From ASH 2015: Developments in CAR T-Cell Therapy   Dr Miguel-Angel Perales highlights the most important data on CAR T-cell therapy presented at the ASH 2015 annual meeting.
  • Acute Leukemia Takeaways From ASH 2015: New Agents   Dr Farhad Ravandi provides an overview of the highlights in acute myeloid leukemia and acute lymphoblastic leukemia from the 2015 American Society of Hematology Annual Meeting.
  • American Society of Hematology (ASH) 57th Annual Meeting Read clinically focused news coverage of key developments from ASHP 2015.
  • ASH CAR T-Cell Therapy at ASH 2015: What's Hot A preview of the most important research on CAR T-cell therapy at the ASH 2015 annual meeting.
  • What to Expect in Hematologic Malignancies   Dr Bruce Cheson previews the most important trials being presented at ASCO 2015 on Hodgkin's and non-Hodgkin's lymphoma, acute and chronic leukemia, and multiple myeloma.
  • Ancestry Data in Cancer: Predictive, Prognostic, or Both?   Dr. Maurie Markman considers how genetic ancestry data might be used to predict risk for cancer relapse and inform potential ways to mitigate that risk.
  • Off and On Again Story of Ponatinib in CML Dr. Michael Deininger reviews data from ASH 2013 on ponatinib in chronic myeloid leukemia, and discusses the drug's future in view of the recent FDA decision to suspend -- and reinstate -- approval.
  • Is Obinutuzumab the Drug to Watch in CLL? Drs. Cheson and Czuczman highlight data on obinutuzumab, ibrutinib, idelalisib, and emerging agents that are reshaping the leukemia and lymphoma landscape.
  • Risk for Leukemia After Breast Cancer A new study shows that younger women had the highest risk for myelodysplasia or acute myeloid leukemia after a diagnosis of breast cancer.
  • 18th Congress of the European Hematology Association (EHA) Read clinically focused news coverage of key developments from EHA 2013.
  • New Therapy Unleashes 'Serial Killer' Cells in Leukemia Adoptive immunotherapy is providing exciting preliminary results in leukemia patients. Leading researcher Dr. Carl June explains the therapy and its potential application to other cancers.
  • ALL: Exciting New Therapy   CART offers promise even for children with the most refractory disease.
  • Bortezomib Combo Keeps on Giving in Myeloma   Dr. Martin Dreyling highlights presentations in blood cancers at ESMO 2012, including important findings on bortezomib, combinations of prognostic markers, and ways to deliver personalized treatment.
  • Can Genetics Predict Chemo Dose Response in AML?   Genetic profiling is used in patients with acute myeloid leukemia to predict prognosis. Dr. Maurie Markman looks at how it can also be used to predict response to chemotherapy.
  • Blood Cancers: What to Look for in Leukemia   Dr. Bruce Cheson highlights noteworthy studies, new drugs, and impressive data in ALL, CLL, and CML that will be discussed at ASCO® 2012.
  • Crossing Boundaries in Molecular Therapy: HER2 in ALL   Looking at a recent report describing the use of trastuzumab in HER2-positive ALL, Dr. Maurie Markman considers what this means for the future of molecular-targeted cancer therapy.
  • Incredibly Shrinking Risk for Secondary AML   Dr. Maurie Markman reports on a study indicating that risk for therapy-related AML in ovarian cancer patients has declined dramatically since the 1980s. Is it because of increased paclitaxel use?
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.